Core Viewpoint - Sichuan Hebang Biotechnology Co., Ltd. faces dual accountability from the Sichuan Securities Regulatory Bureau and the Shanghai Stock Exchange for financial accounting and information disclosure violations, with a projected net loss of 470 million to 570 million yuan for 2025, marking a significant decline from profits exceeding 6.8 billion yuan in 2021-2022 [1][2][4]. Financial Violations - Hebang Biotechnology prematurely recognized revenue of 3.7326 million yuan for 2024, leading to an overstatement of income [2] - The company also provided inaccurate information regarding the issuance of convertible bonds to unspecified parties for 2024 [2] - The Sichuan Securities Regulatory Bureau issued warning letters to the company and its key executives, including the controlling shareholder and the general manager, for these violations [2] Performance Decline - The company experienced explosive growth in 2021-2022, with revenues of 9.867 billion yuan in 2021 (up 87.56%) and 13.039 billion yuan in 2022 (up 30.55%), resulting in a total profit of over 6.8 billion yuan [4] - However, net profit plummeted to 1.283 billion yuan in 2023 and further declined to 31.46 million yuan in 2024, with a projected loss for 2025 [4][5] - The anticipated net profit for 2025 is between -470 million and -570 million yuan, indicating a drastic drop in profitability [5][6] Strategic Missteps - The company has faced challenges due to blind expansion during favorable market conditions, leading to increased cash flow pressure and debt burdens [7] - Hebang announced a 12.5 billion yuan investment in a production line in 2022, which has since faced delays and adjustments due to market downturns [7] - Previous investments in solar materials also resulted in project terminations due to industry overcapacity and competition [8] Current Challenges - Hebang Biotechnology is currently dealing with regulatory scrutiny, significant losses, failed expansion projects, and high debt levels [8] - The company aims to address these issues through three strategic directions: increasing phosphate production capacity, enhancing cost control for core products, and strategically divesting underperforming business segments [8]

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我 一、信披违规被立案 1月27日晚间披露2025年度业绩预告，预计2025年归母净利润亏损1亿元至1.4亿元，上年同期亏损1.79亿 元；扣非净利润亏损7000万元至9500万元，上年同期亏损1.09亿元。 业绩不尽如人意之外，该公司还于2025年11月21日发布公告称因涉嫌信息披露违法违规被证监会立 案调查。依据相关法律法规，符合于2025年11月21日（含当日）之前买入，并在2025年11月22日之后卖 出或仍持有而亏损的即可报名加入维权行列。（豪尔赛维权入口） 在资本市场法治化不断推进的今天，"应披尽披、及时披露"不再只是一句口号，而是上市公司肩负的法 定义务，任何试图挑战这一底线的行为都将受到法律的严惩。 责任编辑：韦子蓉 登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finan ...

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我 一、股票被重点监控 1月23日，上交所通报1月19日至1月23日的沪市监管情况。对天普股份（维权）等波动幅度较大的股票 进行重点监控，对20起上市公司重大事项等进行专项核查，向证监会上报涉嫌违法违规案件线索3起。 天普股份作为大牛股引起市场广泛关注，该公司已在1月9日因股票交易异常波动公告涉嫌重大遗漏被立 案调查。并且在此之前多次被监管关注。上交所于2025年12月31日向该公司发出监管工作函，处理事由 为"涉嫌信息披露违规"。 随后公司股价一路下跌，信息披露是资本市场健康有序运行的基础，是投资者作出价值判断和投资决策 的重要依据。真实、准确、完整是对信息披露的基本要求。 暂定符合于2026年1月9日（含当日）之前买入，并在2026年1月10日之后卖出或仍持有而亏损的可 进行索赔登记。该公司面临的不仅是一场信息披露的合规考验，更是一场市场信任与监管权威 ...

Core Viewpoint - Dongyun Co., Ltd. has received regulatory warnings from the Guangdong Securities Regulatory Commission and the Shenzhen Stock Exchange due to violations related to the disclosure of guarantees for loans taken by its wholly-owned subsidiary, leading to significant expected losses in its 2025 financial results [1][3]. Group 1: Regulatory Actions - Dongyun Co., Ltd. was issued a warning letter by the Guangdong Securities Regulatory Commission for failing to timely disclose guarantees related to loans totaling 30 million yuan and 4 million yuan, which were provided by its subsidiary [1]. - The company and its executives, including Chairman Yang Haikun and General Manager Zhang Furu, are held primarily responsible for these violations and have been urged to improve compliance with regulations [1][2]. - The Shenzhen Stock Exchange has also issued a regulatory letter to the company, emphasizing the need for strict adherence to information disclosure obligations [3]. Group 2: Financial Performance - The company expects a net loss attributable to shareholders of between -18 million yuan and -13 million yuan for the fiscal year 2025, compared to a profit of 5.13 million yuan in the previous year [3][4]. - The net profit after excluding non-recurring gains and losses is projected to be between -10 million yuan and -7 million yuan, a significant decline from -567,000 yuan in the same period last year [4]. - The decline in profits is attributed to a substantial decrease in gold mining production and sales, as well as a loss from the sale of 75% of its stake in Beijing Huanglong Jintai Mining Co., Ltd. [4]. Group 3: Management and Governance - The company has committed to addressing the issues raised by the regulatory bodies by enhancing its internal governance and control systems, as well as improving the quality of information disclosure [2]. - Dongyun Co., Ltd. aims to ensure that future disclosures are accurate, complete, and timely to prevent similar violations from occurring again [2]. Group 4: Additional Context - The company has faced negative publicity recently, including the arrest of its actual controller, Yang Tao, for alleged illegal public deposit solicitation [5].

和邦生物关于2025年半年度募集资金存放与实际使用情况的专项报告显示，根据中国证券监督管理委员会证 监许可[2024]1233号《关于同意四川和邦生物科技股份有限公司向不特定对象发行可转换公司债券注册的批 复》，四川和邦生物科技股份有限公司(以下简称"公司")于2024年10月28日向不特定对象发行4,600万张可转 换公司债券，每张面值100.00元，发行总额4,600,000,000.00元，债券期限6年。公司本次发行，扣除各项发 行费用不含税金额人民币24,599,056.60元后，实际募集资金净额为人民币4,575,400,943.40元，资金到账时间 为2024年11月1日。保荐人(主承销商)为首创证券（601136）股份有限公司。 中国经济网北京1月27日讯四川证监局昨日发布关于对四川和邦生物（603077）科技股份有限公司、四川和 邦投资集团有限公司、贺正刚、曾小平、王军采取出具警示函措施的决定(〔2026〕2号)。经查，四川证监 局发现四川和邦生物科技股份有限公司(以下简称：和邦生物，603077.SH)存在以下问题： 一是和邦生物将部分客户签收确认于2025年的收入确认在2024年，导致20 ...

● 本报记者 昝秀丽 证监会今年开出的"1号罚单"直指操纵市场行为，对自然人余韩操纵"博士眼镜"股价罚没逾10亿元；浙 江证监局对向日葵重组预案涉嫌误导性陈述立案调查；深交所对因涉嫌财务数据存在虚假记载被证监会 立案的*ST立方、*ST长药进行重点监控……近日，一系列监管案例密集公布，彰显出监管部门对市场 违法行为"零容忍"的坚决态度，传递出强化交易监管、维护市场公平、防止大起大落的明确信号。 从行政处罚到刑事追责，从精准打击到平台共治，监管部门正构建起一张多维度、立体化的监管网络， 着力打造"不敢违、不能违、不想违"的长效治理格局，以监管效能的提升推动市场生态持续净化。 严打异常炒作 维护市场稳定运行 无独有偶，同样面临退市风险的*ST长药连续多个交易日涨停。然而，炒作热潮难掩退市定局，*ST长 药1月23日晚间发布的公告称，公司当日收到证监会行政处罚决定书，深交所同步下发事先告知书，明 确拟终止其股票上市。 针对此类乱象，相关部门反应迅速、出手精准。深交所于1月23日明确表态，对因涉嫌财务数据存在虚 假记载被证监会立案的*ST立方、*ST长药进行重点监控。 浙江裕丰律师事务所律师厉健分析，异常波动背后常伴 ...

Core Viewpoint - The company received a warning letter from the Guangdong Securities Regulatory Bureau regarding certain financial practices and disclosures [1] Group 1: Regulatory Actions - The company and its executives, including Yang Haikun, Zhang Furu, Wang Ye, and Hu Lei, were subject to a warning letter due to failures in timely board review and information disclosure related to financial guarantees [1] Group 2: Financial Transactions - The company's wholly-owned subsidiary, Shaanxi Hanyin Huanglong Gold Mine Co., Ltd., applied for working capital loans of 30 million yuan and 4 million yuan from Shaanxi Hanyin Rural Commercial Bank on April 27 and July 18, 2025, respectively [1] - The company provided joint liability guarantees for these loans, but the related guarantee matters were not submitted for board review in a timely manner [1]

每经AI快讯，2026年1月26日，深交所向怀集登云汽配股份有限公司、杨海坤、张福如、王晔、胡磊发 出监管函。 经查，你公司及相关人员存在以下违规问题： 2025年4月27日及2025年7月18日，你公司全资子公司陕西汉阴黄龙金矿有限公司分别向陕西汉阴农村商 业银行股份有限公司申请流动资金借款3000万元及400万元，你公司为相关两笔借款提供了连带责任保 证，但相关担保事项未及时提交董事会审议，也未及时履行信息披露义务，直至2025年9月2日，你公司 才在《关于公司出售资产暨关联交易的公告》中披露相关担保事项。 你公司的相关行为违反了本所《股票上市规则》第1.4条、第2.1.1条第一款、第6.1.10条第一款和《上市 公司自律监管指引第1号——主板上市公司规范运作》第6.2.2条第二款的规定。 你公司董事长杨海坤、总经理张福如、财务总监王晔未能恪尽职守、履行忠实勤勉义务，违反了本所 《股票上市规则》第1.4条、第2.1.2条第一款、第4.3.1条第一款的规定，对你公司相关违规行为负有主 要责任。 （记者 王晓波） 你公司董事会秘书胡磊未能恪尽职守、履行忠实勤勉义务，违反了本所《股票上市规则（2025年修 订） ...

Core Viewpoint - The article discusses the ongoing legal claims against Ronglian Technology due to false statements, with a deadline for investor claims approaching within a week [1][2][3]. Group 1: Legal Proceedings - Ronglian Technology has been implicated in information disclosure violations, having transferred a total of 29.56 million yuan to Beijing Shunlian Technology Co., Ltd. and 15.42 million yuan to Beijing Yunqi Technology Co., Ltd. under the guise of advance payments, with funds later directed to a company controlled by a major shareholder [2][3]. - The law firm Shanghai Jucheng, led by lawyer Xu Feng, is currently accepting claims from investors who purchased Ronglian Technology shares between April 3, 2020, and January 31, 2023, and either sold or continued to hold the shares after January 31, 2023 [2][3]. Group 2: Investor Information - Investors are urged to act quickly as the legal claim period is nearing its end, with only about one week remaining for filing claims [1][2]. - The law firm has previously achieved successful outcomes for investors in similar cases, indicating a potential for compensation for affected investors [4].

1月20日，獐子岛集团股份有限公司（以下简称"獐子岛"）收到大连证监局《行政监管措施决定书》与 深交所监管函。两份监管文件都直指獐子岛未及时披露参股公司普冷獐子岛借款逾期事项。虽然獐子岛 目前已发出催款函，但普冷獐子岛连续亏损、负债攀升的经营现状，也让1450.87万元借款的偿还时间 成了未知数。 业内人士指出，本次事件暴露出獐子岛在内控和信息披露机制上仍存短板。无法收回的借款可能令其财 务状况雪上加霜。目前，獐子岛已连续多年资产负债率超过90%，高资产负债率既不利于企业再融资， 也容易造成较大经营负担。对此，獐子岛已开始通过定增、处置部分资产的方式进行"回血"。 借款逾期公告迟发1月有余 2024年，獐子岛向参股公司大连普冷獐子岛冷链物流有限公司（以下简称"普冷獐子岛"）提供1450.87 万元的财务资助。根据贷款协议，本次财务资助的借款期限为2024年12月11日至2025年12月10日。截至 2025年12月10日，普冷獐子岛未按期还款，但獐子岛未按规定及时履行信息披露义务，迟至2026年1月 15日才披露《关于参股公司借款逾期的公告》。 针对上述情况，2026年1月20日，深交所下发对獐子岛、刘德伟、 ...